Dr Anna Lavelle  
(Chief Executive Officer)  
AusBiotech Ltd

Dr Deborah Rathjen  
(Chairman)  
Bionomics

Dr Peter Isdale  
Transpacific Industries Group

Dr Meera Verma  
Headland Vision

Mr Peter Turvey  
Foursight Associates

Dr Mark Harvey  
CM Capital Investments

Dr Greg Roger  
Advanced Surgical Design & Manufacture Ltd

Dr Paul Walton  
CSL
The 2011–12 financial year has proven to be another significant period for AusBiotech and for the Australian biotechnology industry, with: continued focus on the public policy impacting the sector; a stronger concentration of our commitment to attracting investment in promising Australian biotechnology companies; and the culmination of the anniversary celebrations, marking 25 years since AusBiotech began as the Australian Biotechnology Association (ABA).

Dr Deborah Rathjen
AusBiotech Chair

The strong performance of the biotechnology sector in an unpredictable economic market, underscores the industry’s success, maturation, and resilience. The Australian biotech industry was named the fifth most innovative in the world, by the Scientific American World View magazine in 2011. There’s a buzz amongst investors, most notably about the value offering available here, and increasing activity in mergers and acquisitions, as well as licensing deals.

Public policy
In public policy terms the period began with the momentous news in July 2011 that R&D Tax Incentive had finally won cross-bench support that saw it passed into law in September 2011 and retrospectively effective from 1 July 2011. AusBiotech then turned its attention to the roll-out of the Tax Incentive and continued its work on the ‘gene patent’ debate -which had erupted in early 2011 - to ensure that the mirror Bill in both Houses of the Parliament did not pass and cause far-reaching unintended consequences. When the Senate Inquiry into the gene patents Bill delivered its report in September 2011, which agreed with AusBiotech and the sector that the bill “should not be passed,” there was much to celebrate.

AusBiotech member consultation commenced at the member briefing road-show for the 2011 -12 year, with the July events, which were hosted AusBiotech’s Chief Executive Officer, Dr Anna Lavelle. The events held around the country were attended by more than 200 members and discussed federal policy issues in preparation for the 2012 Federal Budget cycle and to canvas issues impacting AusBiotech members.

As part of these discussions and during the period, two other issues emerged as having importance to the biotechnology sector: the role for medical devices and biopharmaceuticals in Australia’s manufacturing future; and greater access to venture capital funds and superannuation funds. These formed the basis of two consultation policy fora in AusBiotech’s December Policy Summit that brought together industry thought leaders, to determine public policy direction in this regard for the coming one to three years.

The first of the for a concentrated on the funding issues and the second focussed on advanced manufacturing in response to the Prime Minister’s Task Force on manufacturing, the Opposition’s manufacturing strategy development and the NSW Government’s Industry plan, called for by Deputy Premier Stoner, and the Victorian Government’s manufacturing policy in December 2011.

AusBiotech made nine government submissions during the year, including a substantive submission to the Senate Inquiry into ‘The Regulatory Standards for the Approval of Medical Devices.’

Experts from business and industry, including AusBiotech CEO, Dr Anna Lavelle, will oversee the implementation of the R&D Tax Incentive via a Ministerial appointment to the ‘R&D Tax Incentive Advisory Committee’, which has been established to ensure the program provides the intended benefits to Australian industry from increased investment in research and development. I congratulate Anna on this appointment, which ensures AusBiotech and its members are involved and able to provide feedback as the Program is rolled out.

I’m also pleased to report that AusBiotech was again hosted at Parliament House for the annual CEO Forum in March. A number of my fellow Directors and 20 of AusBiotech’s member CEOs and executives were addressed by a range of speakers on innovation policy and programs, including the Hon Greg Combet, Minister for Industry and Innovation and Minister for Climate Change and Energy Efficiency, the Hon Catherine King, Parliamentary Secretary for Health and Ageing and Senator Kate Lundy, Minister for Multicultural Affairs and Minister assisting Industry and Innovation.
Attendees received updates on programs in the Department of Industry, Innovation, Science, Research and Tertiary Education (DIISRTE), Commercialisation Australia and the Department of Health and Ageing (DoHA), including information for the Therapeutic Goods Administration and IP Australia.

The Forum is a valuable opportunity for dialogue on public policy issues that impact upon and will shape the future of the biotechnology industry in Australia and for members to provide comments and feedback directly to the Federal Government.

25 year celebrations

Almost 400 people gathered for the industry’s night of nights and celebrated 25 years since AusBiotech began as the ABA in support of a now highly-successful Australian biotechnology industry.

The fitting celebration dinner, held on 3 August in the Melbourne’s prestigious Plaza Ballroom, featured the key note speech from Professor John Shine - winner of the nation’s most highly-respected award for scientific achievement, the 2010 Prime Minister’s Prize for Science. He is head of Sydney’s Garvan Institute of Medical Research and on the Board of Australia’s leading biotechnology company, CSL (and has since become Chairman).

A purpose made short-film screened interviews with Dr Martin Playne, founding President of the ABA, Dr Brian McNamee, CEO of CSL, The Hon John Brumby, former Victorian Premier, Dr EsraOgru, CEO of Phosphagenics and Dr Anna Lavelle, CEO of AusBiotech.

Messages came from around the country from researchers, parliamentarians - past and present - and company CEOs, which were read by Dr Peter Riddles, the inaugural President of AusBiotech. The messages included well wishes from distinguished Australians, such as Professor Ian Frazer, the Hon Peter Beattie and Sir Gus Nossal.

Along with my address as Chairman, Dr Simon Carroll, the inaugural Chair of AusBiotech, made a toast to honour all those whose contribution AusBiotech has built on and will continue to build upon, and made special posthumous tribute to the Hon John Button and Dr Mike Dalling.

I note that AusBiotech and the biotechnology community mourned the tragic loss of respected three AusBiotech members, Dr Alistair Murdoch in August 2011, Dr Mike Hirshorn in November 2011 and Dr Andrew Baker in March 2012.

Dr Alistair Murdoch was the CEO of Spirogene, a West Australian R&D company focused on developing sustainable solutions for animal health, an active member of AusBiotech, and Director of a number of life science biotechnology companies, including Dimerix, Glycan, Scicom Australia and NemGenix.

Dr Andrew Baker passed away a few days short of his 51st birthday, while a partner with GBS Ventures, where he had worked since 2002. He had sat on the boards of several biotechnology companies, including Hatchtech, Spinifex, Verva, Euthymics and Xenome.

Dr Michael Hirshorn, a leader and pioneer in the life science industry and co-founder of Cochlear and ResMed, lost his battle with cancer. He had spent over 30 years in the life science industry, from its earliest stages in this country, and helped drive some of its greatest successes.

Industry development and events

Biotechnology companies and international investors reported excellent results from the AusBiotech annual conference, with programs and activities dedicated to helping companies and researchers connect with investors and partners, stirring substantial international interest.

AusBiotech 2011 was held in Adelaide in October 2011, with more than 1,100 participants, the event facilitated over 2,300 partnering meeting requests and again featured the Australasian Life Sciences Investment Summit, the biggest investment event of its kind in this part of the world, which attracted 120 invited investors - almost half from overseas.

The AusBiotech investment series has gone from strength to strength with regular annual showcases now scheduled for the USA and Australia. This year also saw AusBiotech make its first foray into Europe with an Australian delegation providing a showcase for European investors in late 2011.

AusEvents, which was launched in June 2011, to provide a full and professional conference organising service for life science and technology events, held its first contracted event during the period, for the Biofuels Association of Australia. Interest in the service has been strong, and a number of booking for future events have now been made, including a contract to organise the Research Australia 2012 Philanthropy conference.
Board

This is my fourth annual report at Chairman and I was pleased to be both re-elected during the period and re-appointed as Chairman of the AusBiotech Board. I'm delighted to be serving again on the Board of AusBiotech and humbled by the confidence the members have shown in me.

The election results were announced at the October 2011 Annual General Meeting (AGM) in South Australia, after elections were held for two positions on the Board. Along with my re-election, Mr Peter Turvey was elected to help lead the industry organisation in its advocacy. Dr Meera Verma was appointed as the chair of the Risk and Audit Sub-Committee (RaSC), while Ms Geraldine Farrell and Dr Stewart Washer retired from the Board.

Peter Turvey was formerly the Manager of Intellectual Property and Company Secretary of CSL, and is currently a Principal at Foursight Associates. After completing his law degree, Peter went into private practice and in 1984 joined Biotechnology Australia, then Australia's largest biotechnology company, as the Manager of Intellectual Property and Company Secretary.

In 1992, Peter joined CSL as its first in-house Corporate Counsel and was appointed Company Secretary in 1998. Peter was involved in CSL's largest commercial transactions, including the acquisition of ZLB and Aventis Behring and divestment of CSL's animal health business to Pfizer.

Geraldine Farrell, who had been on the Board and on the RaSC for three years and Chair of the RaSC for 12 months, has helped the Board in so many ways, in particular in framing the constitution, which has now been adopted in its new form. She has also brought a deep understanding of corporate governance and risk management, to ensure that AusBiotech's systems and processes are appropriate.

Stewart Washer contributed three years’ service to the Board, and was a member of the RaSC for one year.

He brought to the Board and the RaSC an understanding of the investment community, and of what being a CEO of a small biotech company means in reality. He had a pragmatic approach to the issues faced by small companies.

At the end of May 2012, AusBiotech announced the invited appointment to the Board of well-respected investment manager and venture capitalist Dr Mark Harvey, to assist in its efforts to grow and attract capital to the biotechnology industry.

The appointment reflects AusBiotech's focus on the attraction of capital to the sector and supports the work being undertaken at a policy level and in the AusBiotech global investment series, which provides a platform for Australian companies seeking partnering and investment.

Dr Mark Harvey is a Partner with CM Capital Investments, one of Australia's leading venture capital companies with over $250 million under management. Mark has over 20 years’ experience in medical research, technology transfer and commercialisation, and has played key roles in the formation, fund raising, and management of numerous life science companies. Mark is a member of the Board of Directors of Sunshine Heart, Osprey Medical Inc, and Pathway Therapeutics Inc.

On behalf of the Board, I’d like to thank the management and team at AusBiotech for their contribution and hard work. An organisation’s success is the result of its people, without whom AusBiotech could not have achieved what is has.

As a member of AusBiotech, you can look forward to a Board and team, under Dr Anna Lavelle’s leadership, that will be proactive, deliver results, vigilant and values your feedback and support.

DR DEBORAH RATHJEN
CHAIRMAN

REFRESHED LOGO

A refreshed AusBiotech logo was launched in January 2012. The trade mark image has been updated with a new lime and charcoal colour palette while retaining its previous form exactly. The new look reflects a renewed commitment at AusBiotech to grow and sustain the industry and to represent its membership and superseded the teal green that had represented AusBiotech since its inception in 2001.
This was a year of milestone achievements for AusBiotech and I’m pleased we have been able to deliver to your bottom line with the R&D Tax Incentive becoming a reality, to provide new cash flow to the sector – and AusBiotech was instrumental in the policy adoption of quarterly payments, which the Government will work to implement by 2014. We have also worked diligently to protect the industry’s viability against the “gene patent campaign” after The Patent Amendment (Human Genes and Biological Materials) Bill 2010 sought to ban patents over any biological materials which are identical or substantially identical to what exists in nature.

**Patents**

We argued that the Bill was flawed because it did not address, let alone solve, the issues it sought to. After more than 12 months of advocacy and campaigning, that included submissions and giving evidence at the Senate Inquiry hearing, the Senate Legal and Constitutional Affairs Legislation Committee’s Inquiry recommended that the Bill should not be passed in late 2011.


We congratulated the Government on responding to these previously unaddressed reports, which allowed us to move forward with greater clarity by providing improvements to intellectual property management in Australia. Patents are a key incentive for investment in research and development and a strong patent system will provide confidence and encourage the significant investments in biotechnology innovation, while ensuring access for patients to new treatments, diagnostics and to researchers to continue their work.

In its report, the Government noted that a number of recommended changes and actions that were to be addressed through the ‘Raising the Bar’ Bill, which was at the time in the Senate awaiting passage. In April 2012, the ‘Intellectual Property Laws Amendment (Raising the Bar) Bill 2011’ was passed into law in the Australian Parliament, heralding an improvement in IP management in Australia – by providing more certainty for researchers and harmonising patent management with international standards. The Bill’s key changes of interest were:

1. Raising the standards for the grant of patents, to be more closely aligned with international standards, giving innovators more certainty when applying for protection overseas;
2. Free access to patented inventions for regulatory approvals and research. This ‘research exemption’ allows researchers to conduct their research with the certainty that they aren’t infringing on the patent rights of others;
3. Simplifying the IP system to get rid of unnecessary hurdles in the application process.

**R&D Tax Incentive**

Once the R&D Tax Incentive commenced, provisions for applications for advance findings were significantly extended, to give companies certainty and guidance – and the process opened for applications.

The biotechnology industry welcomed the news that the new legislation now allows, with the pre-approval of Innovation Australia, a claim of up to 50 per cent on an R&D project conducted overseas, which has been raised from 10 per cent ceiling that was available under the now superseded tax concession. The provision is available to R&D tax incentive claims if the activity cannot be conducted in Australia and (only) if it is given advanced approval by Innovation Australia.

In addition, companies may now apply for a finding to determine whether an activity conducted either in Australia or overseas is an R&D activity (core or supporting) under the definition of this program. This addition will give companies the opportunity to be certain of a claim before commencing and R&D project. We strongly support the ability to have activities pre-approved, as small and start-up companies cannot afford to get it wrong. We expect this feature of the program will
be in demand and Innovation Australia has undertaken to provide determinations within 90 days of application. We are interested in your feedback regarding this process in the future.

CEO Industry Position Survey 2012

The annual AusBiotech survey of CEOs and senior managers, conducted in early 2012, on three topics – sentiment, funding and public policy – showed that sentiment for the industry’s future continues to run high. The vast majority of respondents (82%) expect their business to grow in 2012, with 68% characterising 2011 as a good or excellent year.

However, the operating environment – both economic and public policy – remained a concern for the growth of biotechnology companies, with two in five companies (38%) saying that the operating environment was working against their growth.

The survey, which was supported by Grant Thornton, asked which issues most concerned CEOs at a federal level, and to name the thing they want most from the federal government to assist the industry. Among the major industry concerns and desired assistance, the themes of note were: incentives for investment; a greater quantum of targeted funding support; and predictability in relation to policy and programs.

Access to significant tranches of capital remains the biggest issue for the biotechnology industry. While programs such as the R&D Tax Incentive, the Innovation Investment Fund (IIF) and Commercialisation Australia (CA) grants all help, there remains a gap in terms of incentives for investors.

The industry is still seeking a greater quantum of targeted funding support that would provide access to adequate-sized grants for commercialisation activities and clinical trials. Biotechs (and innovation more generally) would benefit greatly from incentives for investors in the form of tax breaks. An incentive for investors to invest in innovation-based companies, and to hold their investment for a minimum period, would drive behaviour and be impactful.

A major theme in CEOs’ comments was the notion of stability, certainty and a plea to governments to keep support programs, and keep them predictable. Respondents asked for the maintenance of current policies, as the changing of “goal posts” is disruptive, and prevents companies from making reliable forecasts.

Demonstrating that biotechnology is intimately linked to manufacturing in Australia, the majority of responding companies (62%) are manufacturing, with 46% manufacturing in Australia and 34% manufacturing overseas, with a crossover 18% of companies that manufacture both overseas and in Australia.

As it does each year, the survey’s findings provide policy direction for AusBiotech’s work. We will continue working to improve incentives for investors and at policy changes that will improve the business environment in Australia.

Representation to governments

As well as continuing to represent the industry on the Pharmaceuticals Industry Council and as a Ministerial Appointment to the National Enabling Technology Strategy's Stakeholder Advisory Council, I’m pleased to have been appointed to the Minister’s R&D Tax Incentive Advisory Committee. In addition, on late 2011 the Victorian Minister for Technology Gordon Rich-Phillips announced my appointment to Victoria’s inaugural biotechnology advisory council, which is chaired by Professor Ian Gust.

The Victorian Biotechnology Advisory Council (VBAC) will provide advice to government on current and emerging opportunities and threats to the sector, as well as contributing to the implementation of the Victorian Coalition Government’s biotechnology policy.

Membership benefits

Despite difficult conditions for the industry, AusBiotech is pleased to have been able to extend its level of representation, the services members have come to rely upon, and to grow and improve member benefits. In parallel to its important advocacy on behalf of the industry, AusBiotech initiatives of note this year include:

- Continued expansion of the investment platform events showcasing member companies. Now branded ‘AusBiotech Investment’, the investment series has expanded from its base in Australia and the US, to offerings in Europe and Asia. The Hong Kong investor showcase in June included the signing a memorandum of understanding (MOU) between AusBiotech and the Hong Kong Biotechnology Organisation (HKBIO), which is expected to boost cooperation between Hong Kong and Australia. AusBiotech Investment is also working to further support and add value to its meetings and has struck a partnership with Orient Capital’s Open Briefing to record and publish presentations on an ongoing basis.
The previously launched AusEVENTS, a professional conference organising (PCO) business for science and technology events, held the Alternative Fuels Summit in late 2011 as its first contracted event and has now secured bookings for further events.

During the period AusBiotech announced a new partnership with Australian Life Scientist (ALS) to provide members with a dedicated biotechnology e-news service twice a week, after the joint venture on Biotechnology News ended. ALS is perhaps best known for its magazine, which has a 15-year heritage in reporting across all areas of the life sciences research, and includes current news from the sector, along with in-depth features, profiles of leading scientists and biotechnology companies, and the latest in laboratory technology.

The Business Solutions Program, providing special offers on products and services that are essential to their business operations, has expanded its offering. For example, Chubb provides AusBiotech members with a five per cent discount on the cost of property, general liability and clinical trials insurance products.

AusBiotech has extended networking opportunities in states based on the ‘BioBeers’ model. In particular extra meetings are now being held in Sydney and a dedicated medtech version has commenced on a monthly basis.

A dedicated membership portal has now commenced operation, enabling members to change their details in a secure online environment, accessible from the AusBiotech website. It also enables members to register for events without re-entering details each time.

Staff and committees
AusBiotech’s dedicated staff has risen to the challenge of maintaining and expanding service delivery as its size contracted over the past year, from 20 to 15 positions.

During the period we welcomed Harpreet Kaur to the role of Finance Officer and Michelle Nicolson to support the work of the West Australian Branch Committee as the new Industry Development Officer.

Thank you to the staff we have farewelled during the period: Rachel Jackson, Karen Lo, Christopher Ozga, Holly Beattie, Misha Prusa, Samir Rane, and Dr Olgatina Bushi.

AusBiotech’s work is supported by more than 100 volunteers that work around the country on state-based industry development and on advisory groups dedicated to specialist areas. We were pleased to announce new Chairs for the Branch Committees in Western Australia (WA) and Victoria. We welcomed Mr Brian Leedman, the VP of Investor Relations at pSivida Corp as the Chair of WA and Dr Esra Ogru, CEO of Phosphagenics as the Chair in Victoria.

Responding to members’ needs the AusMedtech Advisory Group and AusBiotech formed and launched the Health Economics Expert Panel (HEEP) to advise on key issues affecting medical devices companies regarding the assessment and reimbursement of medical devices and diagnostics in Australia. HEEP is chaired by Mr Warren Bingham, President of Australia and New Zealand at Given Imaging and Chair of the AusMedtech National Advisory Group and comprises up to 10 appointed members.

Together, the Board, staff, committees and advisory groups all contribute to enable AusBiotech to be the dynamic and committed organisation that it is, supporting and growing the biotechnology industry in Australia and serving AusBiotech members. I thank the Board for their substantial contribution.

As the 25 year celebrations draw to a close, I would like to thank everyone who has contributed to and supported the organisation and the industry – this year and in every one of the past years. We look forward to many more successes in the coming year and to your continued support.

DR ANNA LAVELLE
CHIEF EXECUTIVE OFFICER
INDUSTRY’S WHO’S WHO GATHER FOR 25 YEAR CELEBRATION

Almost 400 people gathered on 3 August 2011 to celebrate 25 years since AusBiotech began as the Australian Biotechnology Association (ABA) with the who’s who of the biotechnology industry.

The celebration dinner, held in the Melbourne’s prestigious Plaza Ballroom, featured the key note speech from Professor John Shine - winner of the nation’s most highly-respected award for scientific achievement, the 2010 Prime Minister’s Prize for Science, a purpose made video featuring interviews, including comments from Dr Martin Playne, founding President of the ABA.

“AusBiotech has led the charge, ensuring that government and academia are aware of the opportunities presented by biotechnology, and the requirements for local success in the field.”

“Organisations are nothing without people... I am sure that with their efforts, the next 25 years will be even more successful for the Australian biotechnology industry.”

Professor Ian Frazer,
Former Australian of the Year and eminent Australian researcher

Professors John Shine & Nancy MMis
“Congratulations to AusBiotech on its 25th anniversary... I have a strong respect for the work of AusBiotech and the biotechnology sector, both as a member of Parliament and former Industry Minister, and as an Australian who has benefited from the wonders of medical research and development.”

“While not all of your remarkable achievements may be discussed in the media or in homes across Australia, the extraordinary leaps in technology that have been made during the past 25 years ensure that when Australians do hear more about biotechnology they come to each development with a sense of awe and fascination.”

The Hon Ian Macfarlane,
Shadow Minister for Energy and Resources

“Everyone who has ever taken a shower has had an idea. It's the person who gets out of the shower, dries off, and does something about it that makes a difference.”

“Thank you all at AusBiotech for getting out of the shower and doing something big with biotech in Australia.”

Alan Liddle, Chief Executive Officer,
of Immune Systems Therapeutics
shared a quote from Nolan Bushnell -
founder and inventor of Atari Computers

“Congratulations on AusBiotech reaching this wonderful 25 year milestone. The organisation is making a major contribution to a burgeoning Australian industry. With a multitude of recent triumphs, biotech has really come of age in this country, combining therapeutic success with commercial progress. The immediate future looks even brighter.”

Sir Gustav Nossal,
Former Australian of the Year and eminent Australian researcher

“As we look to the future, it is critical that Australia continues to invest strongly in Australian research. The commercialisation of brain power is fundamentally important to our place in the world and our economic growth.”

The Hon Peter Beattie,
former Premier of Queensland
GOVERNMENT AFFAIRS AND ADVOCACY

AusBiotech maintained a strong voice on behalf of industry and celebrated two major gains during the year. The R&D Tax Incentive passed into law in September 2011 and was retrospectively effective from 1 July 2011, providing a landmark reform and significant support for the industry. AusBiotech then turned its attention to the roll-out of the Tax Incentive and continued its work on the ‘gene patent’ debate - which erupted in early 2011. The ‘gene patent’ Bill, mirrored in both Houses of the Parliament caused concern in the sector as its passing could have caused far-reaching and unintended consequences. When the Senate Inquiry into the Bill delivered its report in September 2011, which agreed with AusBiotech and the sector that the bill “should not be passed,” there was a collective sigh of relief.

CEO Summit at Parliament House

AusBiotech was again hosted at Parliament House in March for the annual CEO Forum, with AusBiotech Directors and 20 member CEOs and executives addressed by a range of speakers on innovation policy and programs, including the Hon Greg Combet, Minister for Industry and Innovation and Minister for Climate Change and Energy Efficiency, the Hon Catherine King, Parliamentary Secretary for Health and Ageing and Senator Kate Lundy, Minister for Multicultural Affairs and Minister assisting Industry and Innovation. Attendees received updates on 12 programs in the Department of Industry, Innovation, Science, Research and Tertiary Education (DIISRTE) and the Department of Health and Ageing (DoHA).

Submissions

AusBiotech made submissions to governments on policy issues affecting the sector, with nine substantive submissions across a range of industry issues and consultations, including tax, ASX rules, gene technology and regulatory issues impacting medical devices.

- 29/07/2012 - Senate Inquiry into the Regulatory Standards for the Approval of Medical Devices
- 16/08/2012 - The Inquiry into a State-Based Reform Agenda
- 22/09/2012 - Reforms in the medical devices regulatory framework
- 08/08/2012, 15/08/2012 & 15/11/2011 - NSW Health and Medical Research Strategic Review (Phases 1-3)
- 31/01/2012 - AusBiotech Submission on R&D Tax Incentive Implementation – Consultation on Discussion Paper
- 31/01/2012 - Patent Disclosure Requirements under discussion with the World Intellectual Property Organisation’s Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC)
- 10/03/2012 - Prime Minister’s Taskforce on Manufacturing
- 14/05/2012 - ASX’s proposed change to raise limit for capital raising in Annexures 5

AusBiotech on advisory and working groups

AusBiotech continued its representative work on various government working/advisory groups, including the Clinical Trials Action Group and the Pharmaceutical Industry Council. Dr Anna Lavelle was – via a Ministerial appointment – invited to join the oversight of the implementation of the R&D Tax Incentive on the ‘R&D Tax Incentive Advisory Committee’, was appointed to the newly-launched Victorian Biotechnology Advisory Council and joined the Board of Research Australia.
PUBLICATIONS, MEDIA AND COMMUNICATIONS

Annual Biotechnology Industry Position Survey
The annual Biotechnology Industry Position Survey, conducted in February 2012 and launched in April, showed the positive sentiment for the industry’s future continued from the previous year, despite the operating environment (economic and public policy) remaining a concern.

Confidence continued with 82% of respondents expecting their business to grow in the coming year, while 68% characterised last year as a good or excellent year. The expansionary approach to employment that emerged during 2009 persisted, with a majority of companies (58%) indicating they will increase staffing numbers in the coming year.

However, the Australian operating environment (economic and public policy) remains a concern for the growth of biotechnology companies, with two in five companies (38%) saying it was working against their growth.

65% of companies were confident that the passing of the R&D Tax Incentive legislation would have a positive impact on their business. The Federal Government was urged to consider: further incentives for investment; a greater quantum of targeted funding support; and provide predictability for policy and programs. Collectively the 50 responding biotechnology companies plan to spend at least $610 million on research and development in 2012.

Media engagement and ‘voice’
Media engagement remained a priority with a strong and diverse body of coverage providing a ‘voice’ for AusBiotech members on issues of importance to the industry with comments and interviews, resulting in more than 100 articles in national agenda-setting and high-circulation publications, websites and broadcasts, such as the Australia Financial Review and Sky News.

AusBiotech issued 48 media releases in the period and wrote a number of op-ed pieces for industry publications. Copies of media releases and coverage can be found on the AusBiotech website in the press room at www.ausbiotech.org/pressmedia

Keeping members up to date
AusBiotech plays a key role keeps in keeping members up-to-date with industry news, which happens in a range of ways, including member alert emails, the AusBiotech website (www.ausbiotech.org) the AusBiotech journal, Australasian Biotechnology, and via social networking sites LinkedIn and Twitter.

In late 2011, AusBiotech announced a new partnership with Australian Life Scientist (ALS), which provides members with a dedicated biotechnology e-news service twice a week, each carrying an update from AusBiotech as well as industry and life science news from ALS Editor, Tim Dean.

AusBiotech website
The AusBiotech website remains a dynamic forum for news and information in the industry, as well as a resource where press releases, press clips, reports, AusBiotech events and submissions can be accessed. A secure area for members only is under construction and is expected to be functional in the coming year.
Journal and news
Two editions of the AusBiotech Australasian Biotechnology e-journal were released over the 11/12 financial year, publishing issues in October 11, March 12, both of which were published in hard copy.

AusBiotech continued to provide two member updates each week, via a new partnership with Australian Life Scientist (ALS), after the joint venture with Aspermont to produce Biotechnology News’ (BTN) concluded.

Linked In & Twitter
AusBiotech has two authorised social media groups on LinkedIn - the ‘AusBiotech, Australia’s Biotechnology Organisation’ group and the ‘AusMedtech Australian Medical Technology’ group - and two on Twitter. The groups share industry information as it comes to hand, and together the groups have in excess of 2,000 members. The groups continue to growing steadily and a link is available from the AusBiotech website.

Australian directories of biotechnology
AusBiotech hosts two national directories, profiling a wealth of information on hundreds of diverse and innovative biotech and medtech companies doing business in Australia.

The two online directories – The Directory of Australian Biotechnology and The Directory of Medical Devices and Diagnostics – are both available on the AusBiotech website (www.ausbiotech.org). They are free to access and free to list.

Quarterly webcasts
PricewaterhouseCoopers meets with AusBiotech quarterly to produce industry update webcasts, with interviews based on the quarterly publication of the BioForum report.
AUSBIOTECH INVESTMENT

AusBiotech Investment offers a comprehensive series of national and international investor events as a global platform for Australian life sciences companies to showcase their company’s offering for partnership and investment.

Australasian Life Science Investment Summit 2011

The third Australasian Life Science Investment Summit (ALSIS) 2011, was held in conjunction with AusBiotech 2011 in Adelaide. The annual event is the largest investment event of its kind in the Southern Hemisphere, showcasing the 40 most promising Australian biotechnology companies actively seeking capital or partnering opportunities. The event attracted over 120 bone fide investors, with half travelling from overseas to attend the event. Independent research was conducted at ALSIS 2011 showed that at the end of the meeting AU$228 million worth of deals were in discussion (see research findings below).

Independent survey shows value of investment meetings

At AusBiotech 2011, research and consulting firm, Insync Surveys, conducted an independent and confidential review of ALSIS, which has been held annually since 2009. Investors were asked to estimate the value of deals they expect from investment discussions they initiated at ALSIS 2011, and the actual value of deals that were done as a result of the 2010 and 2009 events. The result shows that at the very least, $33 million has been generated for presenting companies. Data for the value expected to be generated from deals in discussion as a result of the 2011 event, suggests the Summit will generate even greater value than previous years.

Hong Kong

An AusBiotech investment mission to Hong Kong in May culminated in the signing of a memorandum of understanding (MOU) between AusBiotech and the Hong Kong Biotechnology Organisation (HKBIO) to boost biotechnology development.

The MOU is to recognise the key role that biotechnology plays in economic and social development, and the benefits of a strategic partnership between Hong Kong and Australia.

Signed by the HKBIO Chairman, Professor Albert Cheung-Hoi YU, and AusBiotech’s Chief Operating Officer, Mr Glenn Cross, the MOU is to promote cooperation in the area of biotechnology, especially where it will assist industry development; and facilitate interaction between Australian and Hong Kong’s parties and officials, scientists and technologists working in the biotechnology sector.
New York
AusBiotech led a New York investment mission, supported by the Australian and Victorian governments and Ernst & Young, prior to the BIO 2012 convention in Boston. The June mission featured 13 companies and was opened by the Honourable Alex Chernov AC QC, Governor of Victoria.

Showcase calendar
AusBiotech Investment held the following investor showcases around the world:

- **Australian Life Science Investment Showcase: New York 2012**
  Friday 15 June 2012 - Ernst & Young Corporate Headquarters, 5 Times Square, New York, United States

- **Australian Life Science Investment Showcase: Hong Kong 2012**
  23 May 2012 - Ernst & Young Corporate Headquarters, CITIC Tower 1 Tim Mei Avenue, Central Hong Kong

- **Medtech Investment Summit**
  14 May 2012 (preceding AusMedtech annual conference)
  - Four Seasons Hotel, Sydney, New South Wales

- **Capital Showcase Brisbane 2012 (with Wholesale Investor)**
  4 April 2012 - PwC office Brisbane, Riverside Centre, Brisbane, Qld

- **'Brokers meet Biotech' Luncheon: Melbourne 2012**
  29 March 2012 - Melbourne Convention Centre, Melbourne, Victoria

- **Cowen’s 2012 Pacific Life Science Showcase: A Fast Fresh Look at Australian & Chinese Companies**
  Monday 9 January 2012 (annexed to JP Morgan Annual Healthcare Conference) - Sir Francis Drake Hotel, San Francisco, United States

- **Australasian Life Science Investment Summit**
  19 October 2011 (in conjunction with AusBiotech national conference) - Adelaide Convention Centre, Adelaide, South Australia

- **Australian Showcase: Amsterdam 2011**
  7 October 2011 - The Mint Hotel, Amsterdam, The Netherlands

- **Life Sciences Showcase 2011 – Sydney (with Wholesale Investor)**
  23 August 201 - NSW Trade & Investment Centre, Martin Place, Sydney

**BUSINESS MISSIONS**

**BIO, Boston**
AusBiotech led a delegation to the industry’s largest global biotechnology event, BIO, returning with positive reports of keen investor interest, which included the Hon Peter Beattie and the Governor of Victoria, the Hon Alex Chernov.

BIO, held 18 - 21 June 2012 in Boston (Massachusetts, US), this year brought together more than 16,500 delegates from 65 countries, 2,000 exhibitors and 2,900 companies. Australian attendees and exhibitors alike spoke highly of the quality interactions and valuable business contacts. Preliminary reporting from the Australia’s exhibiting and other delegates, indicative potential business outcomes from leads was in excess if AU$300 million.

**Medica, Germany**
AusBiotech, for the second year managed the trade presence to the world’s largest trade fair, Medica, which attracted 135,000 visitors to its 17 halls of 4,571 exhibitors from 63 countries.

The Australian Pavilion showcased a diverse range of medical device manufacturers and participating companies negotiated agreements to the potential value of over AU$100 million. The mission was proudly supported by the state governments of Victoria and Queensland and Industry and Investment NSW.
MAJOR EVENTS

AusBiotech 2011
The AusBiotech 2011 national conference, with its theme ‘Creativity, Capability & Capital’ was held in South Australia’s ‘City of Churches’, Adelaide, 16 -19 October 2011. With the support of partners BioInnovation SA and the Government of South Australia, the event attracted more than 1,100 participants, including 233 international delegates from 20 countries, and facilitated over 2,300 partnering meeting requests.

The visit to Adelaide marked the first time the AusBiotech national conference has visited South Australia for eight years. The event commenced with a welcome reception at the Adelaide Oval and continued with a host of satellite events and the comprehensive conference speaker program.

The national conference culminated with the third Australasian Life Sciences Investment Summit, which attracted 180 participants and over 120 investors to view a showcase of selected Australian biotechnology companies. For the first time AusBiotech opened the Summit’s viewing gallery to AusBiotech delegates.

AusMedtech 2012
Australia’s largest medical technology conference, AusMedtech, again attracted 300 delegates to its highly-specialised annual conference for medical devices and diagnostics experts.

AusMedtech 2012 was supported by NSW Trade & Investment and the official opening address was provided by the Hon Marie Ficarra, Parliamentary Secretary to the NSW Premier, Barry O’Farrell. AusMedtech brought together key stakeholders of the Australian and international medical devices and diagnostics sector, to discuss the major issues in global medtech success.

Special features of AusMedtech 2012 included the Medtech Investment Summit, with 11 companies showcased and the Medtech Trade Exhibition. As a further foray into social media and communication technologies, AusBiotech launched the trial of a web app at AusMedtech 2012 that gave delegates access to all the event information in an easy and fun web format.

Business Development Forum 2012
AusBiotech held the annual dedicated Business Development Forum and Workshop (BD Forum) 2012 on the 15 & 16 March at the Radisson Resort on the Gold Coast. The BD Forum is now in its sixth year – proving its relevance to the biotechnology industry – featured a comprehensive program headlined by international “guerrilla entrepreneur”, Jason Avery, owner of Rockpool Enterprises (Cambridge), an investment house he founded in the UK.
BioPro Courses, AusBiotech’s biotechnology-specific professional development program, has now turned three. BioPro Courses allows professionals the opportunity to further develop their skills in biotechnology, thereby supporting the industry and currently offer two course types:

- Face-to-face: classroom style over one or two days;
- In-house: tailor-made courses.

BioPro Courses continued to offer a consolidated offering this year to meet specific industry needs. Delegates at AusBiotech 2011 took the opportunity to attend the two courses in popular demand due to their world-class presenters: BioBasics and Valuation in Biotechnology. BioPro Courses also teamed up with Deloitte to offer Tax Incentive workshops in late 2011 in three states along the Eastern seaboard of Australia.

A survey conducted in early 2012 sought member feedback on how the program is meeting the industry’s professional development needs, and assisted in forward planning. BioPro Courses was established in March 2009 by AusBiotech due to the growth of Australia’s biotechnology sector, across fields of biotechnology, which continues to create demand for more industry specific skills development.

www.ausbiotech.org/bioprocourses

AusBiotech’s recently launched events management business, AusEvents, held its first event in August: The Alternative Fuels Summit 2011: “Fuels for the Real World” on behalf of the BioFuels Association of Australia. Preparations are underway for the second contracted event on behalf of Research Australia.

The venture continued to build on its strengths with AusBiotech’s support, to provide a full and professional conference organising service for life science and technology events, based on industry knowledge and networks.

www.ausbiotech.org/ausevents
AusMedtech

AusMedtech is dedicated to the development, growth and prosperity of the Australian medical technology (device and diagnostics) industry, by providing initiatives to facilitate success in product development, manufacturing and commercialisation, by encouraging links between industry, research, government and advocates on industry issues.

Key highlights 2011/12:

- AusMedtech led the Australian delegation to Medica, the world’s eminent largest health and medical conference, in Dusseldorf, Germany in November 2011. Thirty-six organisations participated under the Australian pavilion. Deals in excess of $100,000 were made.
- Held four events in Victoria and New South Wales to deliver valuable networking opportunities for members.
- Three special interest expert panels were formed:
  - Health Economics Expert Panel, led by Mr Warren Bingham (Given Imaging)
  - Regulatory Affairs Expert Panel, led by Dr Arthur Brandwood (Brandwood Biomedical)
  - Trade Expert Panel, led by Ms Lusia Guthrie (LBT Innovations)
  - AusMedtech National Conference Committee, led by Dr Steve Gourlay (GBS ventures)
- AusMedtech made submissions to governments on policy issues affecting the medtech industry (see Government affairs and advocacy & submissions).
Agricultural, Environmental and Industrial Biotechnology

The Agricultural, Environmental and Industrial (AEI) Biotechnology National Advisory Group is dedicated to increasing the profile of the AEI sector, providing a voice for organisations working within the sector; and facilitating awareness of the key commercial issues facing the sector.

Key highlights 2011/12:
- AusBiotech made submission to the government regarding the ‘2011 Review of the Western Australian Gene Technology Act 2006’
- AusBiotech participated in the Department of Innovation, Industry, Science and Research Food Industry Foresight Workshop.
- The inaugural AEI biotech/AusFoodtech networking event entitled “Biotechnology’s contribution to the future of food, feed, fibre and energy” was held in Melbourne to deliver valuable networking opportunities for members working within the agri-biotech and food sectors including meat and livestock, plant, dairy and horticulture.

AusFoodtech

AusBiotech’s interest in the functional food and nutraceuticals sector began in 2008 during the winding down of the National Centre of Excellence in Functional Foods (NCEFF).

The AusFoodtech National Advisory Group seeks to:
- Provide a voice for the Australian functional food and nutraceutical sector by representing the views and interests of member organisations at a political level to increase funding support of innovative research, including clinical trials, within the sector.
- Represent and support its member organisations by providing expertise and advice as industry advocates on current and emerging issues and trends facing the functional foods and nutraceutical sector in Australia, including but not limited to: product labelling and health claim substantiation.
- Deliver valuable networking and professional development opportunities
- Facilitate awareness of issues surrounding the development and protection of Intellectual Property for smaller, less established companies.

Key highlights 2011/12:
- The inaugural AusFoodtech symposium was held in Adelaide on 18 October 2012. 71 delegates, representing 60 organisations from Australia, NZ, USA, UK, Canada and Taiwan attended.
- Based on the success of the AusFoodtech symposium, the above-mentioned combined AEI biotech/ AusFoodtech networking event was held.
Your Directors present their report on the company for the financial year ended 30 June 2012.

The names of the Directors in office at any time during, or since the end of, the year are:

<table>
<thead>
<tr>
<th>Director</th>
<th>Appointed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms Geraldine Farrell</td>
<td>29/10/2008</td>
</tr>
<tr>
<td>Dr Anna Lavelle</td>
<td>9/06/2005</td>
</tr>
<tr>
<td>Dr Deborah Rathjen</td>
<td>29/10/2008</td>
</tr>
<tr>
<td>Dr Greg Roger</td>
<td>22/12/2010</td>
</tr>
<tr>
<td>Dr Stewart Washer</td>
<td>29/10/2008</td>
</tr>
<tr>
<td>Dr Peter Isdale</td>
<td>25/8/2010</td>
</tr>
<tr>
<td>Dr Meera Verma</td>
<td>22/10/2010</td>
</tr>
<tr>
<td>Dr Paul Walton</td>
<td>22/10/2010</td>
</tr>
<tr>
<td>Mr Peter Turvey</td>
<td>18/10/2011</td>
</tr>
</tbody>
</table>

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

The number of Directors’ meetings and sub committee meetings attended by each of the Directors of the Company during the financial year are:

<table>
<thead>
<tr>
<th>No. of Meetings Held</th>
<th>Board of Directors 6</th>
<th>Risk &amp; Audit Sub Committee 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Deborah Rathjen</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Ms Geraldine Farrell</td>
<td>1 2</td>
<td></td>
</tr>
<tr>
<td>Dr Anna Lavelle</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Dr Greg Roger</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Dr Stewart Washer</td>
<td>1 2</td>
<td></td>
</tr>
<tr>
<td>Dr Peter Isdale</td>
<td>6 2</td>
<td></td>
</tr>
<tr>
<td>Dr Meera Verma</td>
<td>4 3</td>
<td></td>
</tr>
<tr>
<td>Dr Paul Walton</td>
<td>2 2</td>
<td></td>
</tr>
<tr>
<td>Mr Peter Turvey</td>
<td>5 3</td>
<td></td>
</tr>
</tbody>
</table>

The loss of the company for the financial year after providing for income tax (Nil) amounted to $90,062. (2011: Loss $128,877) Appropriate actions have been taken to restore the company to positive trading and cash flows. The company is exempt from paying income tax.

No significant changes in the company's state of affairs occurred during the financial year. The principal activity of the company during the financial year was the provision of services and activities in developing biotechnology in Australia and globally.
AusBiotech Ltd
ABN 87 006 509 726
Directors Report
for the Year Ended 30 June 2012

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

Likely developments in the operations of the company and the expected result of those operations in future financial years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the company.

The company’s operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

The company is limited by guarantee and acts in accordance with the constitution. Therefore no dividends are payable to members.

The Company indemnifies every officer and former officers of the Company in respect of all acts done by a person while an officer of the Company against all liabilities to another person or entity that may arise, unless the liability arises out of conduct involving a lack of good faith. The Company may make a payment in respect of such liabilities including costs, damages and expenses. As at the date of this report the Company maintains an appropriate Insurance Liability Package for Non-profit organizations to cover any such liabilities arising.

No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

Auditor’s Independence Declaration

A copy of the auditor’s independence declaration, as required under section 307C of the Corporation Act 2001 is set out on page 37.

This report is made in accordance with the resolution of the Board of Directors and is signed for and on behalf of the Directors by:

Ms Meera Verma
Director

Dr Deborah Rathjen
Director

Dated this 5th day of October 2012
AusBiotech Ltd  
ABN 87 006 509 726  
For the Year Ended 30th June 2012

Statement of Comprehensive Income

<table>
<thead>
<tr>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue from Ordinary Activities</strong></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Membership Fees</td>
<td>909,384</td>
<td>624,775</td>
</tr>
<tr>
<td>Conferences</td>
<td>2,305,666</td>
<td>2,751,908</td>
</tr>
<tr>
<td>Branch Income</td>
<td>183,284</td>
<td>138,035</td>
</tr>
<tr>
<td>Government Funded Projects - NCRIS</td>
<td>98,558</td>
<td>320,000</td>
</tr>
<tr>
<td>Government Funded Projects - Other</td>
<td>-</td>
<td>218,000</td>
</tr>
<tr>
<td>Communications</td>
<td>32,110</td>
<td>95,792</td>
</tr>
<tr>
<td>Other Revenue</td>
<td>109,183</td>
<td>60,657</td>
</tr>
<tr>
<td></td>
<td>3,638,185</td>
<td>4,209,167</td>
</tr>
<tr>
<td><strong>Non-operating Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest Received</td>
<td>29,398</td>
<td>55,957</td>
</tr>
<tr>
<td></td>
<td>3,667,583</td>
<td>4,265,124</td>
</tr>
<tr>
<td><strong>Expenses from Ordinary Activities</strong></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Employee Benefits Expense</td>
<td>727,978</td>
<td>556,936</td>
</tr>
<tr>
<td>Depreciation and Amortisation Expenses</td>
<td>64,985</td>
<td>47,783</td>
</tr>
<tr>
<td>Conferences</td>
<td>2,129,931</td>
<td>2,340,300</td>
</tr>
<tr>
<td>Government Funded Projects Expend. - NCRIS</td>
<td>161,496</td>
<td>382,413</td>
</tr>
<tr>
<td>Government Funded Projects Expend. - Other</td>
<td>-</td>
<td>306,903</td>
</tr>
<tr>
<td>Communications</td>
<td>36,737</td>
<td>142,893</td>
</tr>
<tr>
<td>Rent</td>
<td>106,858</td>
<td>87,803</td>
</tr>
<tr>
<td>Travelling</td>
<td>114,360</td>
<td>121,772</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>131,400</td>
<td>221,643</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>283,900</td>
<td>185,555</td>
</tr>
<tr>
<td></td>
<td>3,757,645</td>
<td>4,394,001</td>
</tr>
<tr>
<td><strong>(Loss) before Income Tax</strong></td>
<td>(90,062)</td>
<td>(128,877)</td>
</tr>
<tr>
<td>Income Tax Expense</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>(Loss) after Income Tax</strong></td>
<td>(90,062)</td>
<td>(128,877)</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these audited financial statements
### Statement of Financial Position

<table>
<thead>
<tr>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>4</td>
<td>1,646,779</td>
</tr>
<tr>
<td>Trade and Other Receivables</td>
<td>7</td>
<td>234,465</td>
</tr>
<tr>
<td>Current Tax Assets</td>
<td>8</td>
<td>9,010</td>
</tr>
<tr>
<td><strong>Total Current Assets</strong></td>
<td></td>
<td>1,890,254</td>
</tr>
<tr>
<td><strong>Non-Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, Plant and Equipment</td>
<td>9</td>
<td>87,295</td>
</tr>
<tr>
<td><strong>Total Non-Current Assets</strong></td>
<td></td>
<td>87,295</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td></td>
<td>1,977,549</td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and Other Payables</td>
<td>10</td>
<td>187,749</td>
</tr>
<tr>
<td>Current Tax Liabilities</td>
<td>11</td>
<td>47,674</td>
</tr>
<tr>
<td>Provisions</td>
<td>12</td>
<td>77,676</td>
</tr>
<tr>
<td>Other</td>
<td>13</td>
<td>1,586,080</td>
</tr>
<tr>
<td><strong>Total Current Liabilities</strong></td>
<td></td>
<td>1,899,179</td>
</tr>
<tr>
<td><strong>Non-Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>13</td>
<td>40,000</td>
</tr>
<tr>
<td><strong>Total Non-Current Liabilities</strong></td>
<td></td>
<td>40,000</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td></td>
<td>1,939,179</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td>38,370</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retained Earnings</td>
<td></td>
<td>38,370</td>
</tr>
<tr>
<td><strong>Total Equity</strong></td>
<td></td>
<td>38,370</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these audited financial statements.
AusBiotech Ltd  
ABN 87 006 509 726  
For the Year Ended 30th June 2012

Statement of Changes in Equity

<table>
<thead>
<tr>
<th>Retained Earnings</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Balance as at 30th June 2010</td>
<td>257,309</td>
</tr>
<tr>
<td>(Loss) attributable to the entity for the year ended 30th June 2011</td>
<td>(128,877)</td>
</tr>
<tr>
<td>Balance as at 30th June 2011</td>
<td>128,432</td>
</tr>
<tr>
<td>(Loss) attributable to the entity for the year ended 30th June 2012</td>
<td>(90,062)</td>
</tr>
<tr>
<td>Balance as at 30th June 2012</td>
<td>38,370</td>
</tr>
</tbody>
</table>

Cash Flow Statement

<table>
<thead>
<tr>
<th>Note</th>
<th>2012 $</th>
<th>2011 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receipts from Customers</td>
<td>3,948,674</td>
<td>3,896,373</td>
</tr>
<tr>
<td>Payments to Suppliers and Employees</td>
<td>(5,183,731)</td>
<td>(6,766,386)</td>
</tr>
<tr>
<td>Interest Received</td>
<td>29,398</td>
<td>55,957</td>
</tr>
<tr>
<td><strong>Net Cash Inflow (Outflow) from Operating Activities</strong></td>
<td><strong>(1,205,659)</strong></td>
<td><strong>(2,814,056)</strong></td>
</tr>
<tr>
<td>Cash Flows from Investing Activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of Property, Plant and Equipment</td>
<td>(17,548)</td>
<td>(136,975)</td>
</tr>
<tr>
<td><strong>Net Cash Inflow (Outflow) from Investing Activities</strong></td>
<td><strong>(17,548)</strong></td>
<td><strong>(136,975)</strong></td>
</tr>
<tr>
<td>Net increase / (decrease) in cash held</td>
<td>(1,223,207)</td>
<td>(2,951,031)</td>
</tr>
<tr>
<td>Cash and cash equivalents as at 1 July</td>
<td>2,869,986</td>
<td>5,821,017</td>
</tr>
<tr>
<td><strong>Cash and Cash equivalents as at 30 June</strong></td>
<td><strong>1,646,779</strong></td>
<td><strong>2,869,986</strong></td>
</tr>
</tbody>
</table>

The accompanying notes form part of these audited financial statements
1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation
The accounting policies set out below have been consistently applied to all years presented.

The financial report is a general purpose financial report that has been prepared in accordance with Accounting Standards, Australian Accounting Interpretations and other authoritative pronouncements of the Australian Accounting Standards Board and the Corporations Act 2001.

The financial report covers AusBiotech Ltd as an individual not-for-profit entity. AusBiotech Ltd is a company limited by guarantee, incorporated and domiciled in Australia.

The financial report is presented in Australian dollars. The report is authorized for issue by the Directors on the date of the Directors’ Declaration.

The principal activity of the company is the provision of services and activities in developing biotechnology in Australia and globally.

The following is a summary of the material accounting policies adopted by the economic entity in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

Reporting Basis and Conventions
The financial report has been prepared on a going concern and an accruals basis, except for the cash flow information, and is based on historical costs, modified where applicable, by the measurement at fair value of selected non-current assets, and financial assets and financial liabilities.

Accounting Policies

(a) Cash and Cash Equivalents
Cash and cash equivalents includes cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. The company has no bank overdrafts.

(b) Provisions
Provisions are recognised when the company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognized represent the best estimate of the amounts required to settle the obligation at the end of the reporting period.

These notes should be read in conjunction with the attached Auditor’s Report
(c) **Employee Benefits**
Provision is made for the company’s liability for employee benefits arising from the services rendered by employees to balance date. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.
Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits.

(d) **Property, Plant and Equipment**
Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment losses.

The company has no freehold land and buildings.

Plant and equipment are measured on the cost basis less depreciation and impairment losses.

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the assets' employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

**Depreciation**

The depreciable amount of all fixed assets, is depreciated on a straight line basis over their useful lives to the company commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

The estimated effective lives used for each class of depreciable assets are:

<table>
<thead>
<tr>
<th>Asset Type</th>
<th>Useful Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plant and Equipment</td>
<td>3 to 7 Years</td>
</tr>
<tr>
<td>Office Furniture</td>
<td>10 years</td>
</tr>
</tbody>
</table>

The assets carrying values are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.

*These notes should be read in conjunction with the attached Auditor's Report*
An asset’s carrying account is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in the income statement.

(e) **Foreign Currency Transactions and Balances**
Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction.

(f) **Income Tax**
The company is exempt from income tax.

(g) **Impairment of Assets**
At each reporting date, the company reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset’s carrying value over its recoverable amount is expensed to the income statement.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

(h) **Financial Instruments**

**Recognition**
Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related contractual rights or obligations exist.

**Financial Assets at Fair Value through Profit and Loss**
A financial asset is classified in this category if acquired principally for the purpose of selling in the short term or if so designated by management and within the requirements of AASB 139: Financial Instruments: Recognition and Measurement. Derivatives are also categorised as held for trading unless they are designated as hedges. Realised and unrealised gains and losses arising from changes in the fair value of these assets are included in the income statement in the period in which they arise.

**Loans**
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method. The company has no such loans.

*These notes should be read in conjunction with the attached Auditor's Report*
Held to Maturity Investments
These investments have fixed maturities. The company has no held to maturity investments.

Available-for-sale Financial Assets
Available-for-sale financial assets include any financial assets not included in the above categories. Available-for-sale financial assets are reflected at fair value. Unrealised gains and losses arising from changes in fair value are taken directly to equity.

Financial Liabilities
Non-derivative financial liabilities are recognised at amortised cost, comprising original debt less principal payments and amortisation.

Derivative Instruments
Derivative instruments are measured at fair value. The company has no derivative instruments.

Fair value
Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arm’s length transactions, reference to similar instruments and option pricing models. The company has no such investments.

Derecognition
Financial assets are derecognized where the contract for the receipt of cash flows ceases and financial liabilities where related obligations are discharged, or cease.

Impairment
At each reporting date, the company assesses whether there is objective evidence that a financial instrument has been impaired. In the case of available-for-sale financial instruments, a prolonged decline in the value of the instrument is considered to determine whether an impairment has arisen. Impairment losses are recognised in the income statement.

(i) Research and Development
Expenditure during the research phase of a project is recognised as an expense when incurred.

Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.

Development costs have a finite life and are amortised on a systematic basis matched to the future economic benefits over the useful life of the project.
Revenue and Other Income

Interest revenue is recognized on a proportional basis taking into account the interest rates applicable to the financial assets.
Membership fees revenue is apportioned over the applicable period.
Revenue from the rendering of a service is recognized upon the delivery of the service to the customers.
Grants and sponsorship revenue are recognized when the entity has control and all conditions satisfied.

All revenue is stated net of the amount of goods and services tax (GST).

Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the balance sheet are shown inclusive of GST.

Trade and Other Receivables

These represent the principal amounts due at balance date. They are non-interest bearing and collectable on 30-90 day terms.

Trade and Other Payables

These represent the principal amounts outstanding at balance date, non-interest bearing and at cost.

Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

Impact of New and Revised Accounting Standards not yet effective

There have been a number of new and amended Accounting Standards issued by the AASB that are not yet effective. The company has decided not to early adopt any of the new and amended pronouncements.

Critical Accounting Estimates and Judgments

The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

Key Estimates - Impairment

The company assesses impairment at each reporting date by evaluating conditions specific to the entity that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. Value-in-use calculations performed in assessing recoverable amounts incorporate a number of key estimates.

These notes should be read in conjunction with the attached Auditor's Report
Notes to the Financial Statements

2. Business Venture

Included in total revenue of $3,667,583 (2011 $4,265,124) and total expenditure of $3,757,645 (2011 $4,394,001) are the following transactions relative to the marketing business venture with Aspermont Limited which ended in September 2011.

**Revenue**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communications</td>
<td>10,069</td>
<td>30,986</td>
</tr>
<tr>
<td>Other</td>
<td>5,250</td>
<td>21,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>15,319</td>
<td>51,986</td>
</tr>
</tbody>
</table>

**Expenditure**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communications</td>
<td>21,832</td>
<td>100,318</td>
</tr>
<tr>
<td>Subscriptions Transfer</td>
<td>8,750</td>
<td>34,065</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>30,582</td>
<td>134,383</td>
</tr>
</tbody>
</table>

**Net Loss**

(15,263)        (82,397)

3. (Loss)

Loss from ordinary activities before income tax expense has been determined after accounting for:

**Charging as Expense**

Movement in Provisions
- Depreciation
  - Depreciation of Property, Plant and Equipment 64,985 47,783
  - Net Expenses Resulting from Movement in Provisions 64,985 47,783

Remuneration of Auditor
- Audit & review of financial reports 20,020 17,240
  - **Total** 20,020 17,240

**Crediting as Income**

Interest from:
- Other Corporations 29,398 55,957
  - **Total** 29,398 55,957

4. Cash and Cash Equivalents

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash at Bank</td>
<td>950,902</td>
<td>1,154,116</td>
</tr>
<tr>
<td>Bank guarantee (note 17)</td>
<td>59,540</td>
<td>36,060</td>
</tr>
<tr>
<td>Cash at Bank - NCRIS (note 4(a))</td>
<td>636,337</td>
<td>1,604,621</td>
</tr>
<tr>
<td>Cash at Bank - EIF (note 4(b))</td>
<td>-</td>
<td>75,189</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,646,779</td>
<td>2,889,986</td>
</tr>
</tbody>
</table>

*These notes should be read in conjunction with the attached Auditor's Report*
Notes to the Financial Statements

(a) Cash at Bank (National Collaborative Research Infrastructure Strategy) is a specific Government funding account for the NCRIS project

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funds received (including bank interest)</td>
<td>1,953,170</td>
<td>10,404,921</td>
</tr>
<tr>
<td>Funds expended - participants and management fees</td>
<td>1,316,833</td>
<td>8,800,300</td>
</tr>
<tr>
<td></td>
<td>636,337</td>
<td>1,604,621</td>
</tr>
</tbody>
</table>

b) Cash at Bank (Education Investment Fund) is a specific Government funding account for the EIF project

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funds received (including bank interest)</td>
<td>76,376</td>
<td>3,275,190</td>
</tr>
<tr>
<td>Funds expended - participants and management fees</td>
<td>76,376</td>
<td>3,220,001</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>75,189</td>
</tr>
</tbody>
</table>

Cash Reconciliation

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>1,646,779</td>
<td>2,869,986</td>
</tr>
<tr>
<td></td>
<td>1,646,779</td>
<td>2,869,986</td>
</tr>
</tbody>
</table>

5. Cash Flow Information

Reconciliation of Cash Flow from Operations with Loss after Income Tax

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Loss) after Income Tax</td>
<td>(90,062)</td>
<td>(128,877)</td>
</tr>
</tbody>
</table>

Adjustments for Non-Cash components in Loss:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depreciation</td>
<td>63,530</td>
<td>45,953</td>
</tr>
<tr>
<td>Net Loss on Disposal of Property, Plant and Equipment</td>
<td>1,455</td>
<td>1,830</td>
</tr>
</tbody>
</table>

Changes in Assets and Liabilities

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(increase)/decrease in Trade and Other Receivables</td>
<td>604,277</td>
<td>(370,448)</td>
</tr>
<tr>
<td>increase/(decrease) in Trade and Other Payables</td>
<td>(1,780,167)</td>
<td>(2,357,205)</td>
</tr>
<tr>
<td>increase/(decrease) in Provisions</td>
<td>(4,692)</td>
<td>(5,309)</td>
</tr>
</tbody>
</table>

Net Cash Inflow (Outflow) from Operating Activities

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Cash Inflow (Outflow) from Operating Activities</td>
<td>(1,205,659)</td>
<td>(2,814,056)</td>
</tr>
</tbody>
</table>

These notes should be read in conjunction with the attached Auditor's Report.
AusBiotech Ltd
ABN 87 006 509 726
For the Year Ended 30th June 2012

Notes to the Financial Statements

6. Liquidity Risk
Liquidity risk is the risk that the company will encounter difficulty in meeting its financial obligations. Liquidity risk is monitored to ensure sufficient monies are available to meet the company’s contractual obligations as and when they fall due. This process involves the updating of cash flow forecasts, profit forecasts and regular reviews by management and those in governance.

7. Trade and Other Receivables
Trade Debtors 234,465 566,421
Other Receivables - 25,000
Total Trade and Other Receivables 234,465 591,421

The company does not have any material credit risk exposure to any single receivable or group of receivables.

8. Current Tax Assets
GST Paid 9,010 256,331
includes NCRIS 2011 $241,667

9. Property, Plant and Equipment

<table>
<thead>
<tr>
<th>Description</th>
<th>Initial Cost</th>
<th>Accumulated Depreciation</th>
<th>Net Book Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer Equipment</td>
<td>95,870</td>
<td>81,418</td>
<td>14,452</td>
</tr>
<tr>
<td>Less Accumulated Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computer Systems &amp; Software</td>
<td>115,078</td>
<td>63,483</td>
<td>51,595</td>
</tr>
<tr>
<td>Less Accumulated Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office Equipment</td>
<td>27,399</td>
<td>23,184</td>
<td>4,215</td>
</tr>
<tr>
<td>Less Accumulated Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furniture and Fittings</td>
<td>31,661</td>
<td>14,628</td>
<td>17,033</td>
</tr>
<tr>
<td>Less Accumulated Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Plant and Equipment</td>
<td>87,295</td>
<td>19,192</td>
<td>68,103</td>
</tr>
</tbody>
</table>

These notes should be read in conjunction with the attached Auditor’s Report
10. Trade and Other Payables

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sundry Creditors</td>
<td>151,022</td>
<td>430,858</td>
</tr>
<tr>
<td>Other Creditors</td>
<td>28,544</td>
<td>57,072</td>
</tr>
<tr>
<td>Superannuation Payable</td>
<td>8,183</td>
<td>15,935</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>187,749</strong></td>
<td><strong>503,865</strong></td>
</tr>
</tbody>
</table>

11. Current Tax Liabilities

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GST Collected</td>
<td>47,674</td>
<td>71,076</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>47,674</strong></td>
<td><strong>71,076</strong></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Provision for Annual Leave</td>
<td>65,432</td>
<td>77,742</td>
</tr>
<tr>
<td>Provision for Long Service Leave</td>
<td>12,244</td>
<td>4,626</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>77,676</strong></td>
<td><strong>82,368</strong></td>
</tr>
</tbody>
</table>

13. Other

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepaid Memberships / Grants / Sponsorships / Conferences (includes $40,000 non-current)</td>
<td>989,743</td>
<td>1,145,252</td>
</tr>
<tr>
<td>NCRIS Prepaid Government Funds</td>
<td>480,000</td>
<td>1,406,288</td>
</tr>
<tr>
<td>NCRIS Bank Interest - No Entitlement</td>
<td>156,337</td>
<td>440,000</td>
</tr>
<tr>
<td>EIF Prepaid Government Funds</td>
<td>-</td>
<td>75,189</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,626,080</strong></td>
<td><strong>3,066,729</strong></td>
</tr>
</tbody>
</table>

14. Retained Earnings

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Retained Earnings at the Beginning of the Financial Year</td>
<td>128,432</td>
<td>257,309</td>
</tr>
<tr>
<td>Net (loss) after tax</td>
<td>(90,062)</td>
<td>(128,877)</td>
</tr>
<tr>
<td>Retained Earnings at the End of the Financial Year</td>
<td>38,370</td>
<td>128,432</td>
</tr>
</tbody>
</table>

15. Members’ Guarantee

The company is limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of $4 each towards meeting any outstanding obligations of the company.

*These notes should be read in conjunction with the attached Auditor’s Report*
16. Key Management Personnel

Directors’ remuneration
There is no income and benefits received or due and receivable by directors of the company other than the CEO who must be a director under the Constitution. The income and benefits received or due and receivable by key management of the company (inclusive of CEO), and including insurance premiums to indemnify liabilities are:

<table>
<thead>
<tr>
<th>Total Compensation</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Short term benefits</td>
<td>621,665</td>
<td>588,877</td>
</tr>
<tr>
<td>Post employment benefits</td>
<td>53,165</td>
<td>52,099</td>
</tr>
<tr>
<td>Other long term benefits</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>674,830</td>
<td>640,976</td>
</tr>
</tbody>
</table>

17. Auditor’s Remuneration

Proctor Major & Co Pty Ltd were the auditors of AusBiotech Ltd

<table>
<thead>
<tr>
<th>Audit and review of financial reports</th>
<th>20,020</th>
<th>17,240</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>20,020</td>
<td>17,240</td>
</tr>
</tbody>
</table>

18. Contingent Liabilities

Bank guarantee in favour of third party for future conference | 23,480  | -      |
Bank guarantee in favour of third party for rental of premises | 36,060  | 36,060  |
|                                                        | 59,540  | 36,060  |

19. Company Details

The registered Office of the company is:

AusBiotech Ltd
Level 4, 627 Chapel St, South Yarra, Victoria, 3141

The principal place of business is:

AusBiotech Ltd
Level 4, 627 Chapel St, South Yarra, Victoria, 3141
AusBiotech Ltd
ABN 87 006 509 726
For the Year Ended 30th June 2012

Directors Declaration

The Directors of the company declare that:

1. The financial statements and notes, as set out on pages 4 to 17, are in accordance with the Corporations Act 2001:
   a. comply with Australian Accounting Standards; and
   b. give a true and fair view of the financial position as at 30 June 2012 and of the performance for the year ended on that date of the entity.

2. In the Directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors:

Ms Meera Verma
Director

Dr Deborah Rathjen
Director

Dated this 5 day of October 2012
AusBiotech Ltd
ABN 87 006 509 726
For the Year Ended 30th June 2012

Auditors Independence Declaration
Under Section 307C of the Corporations Act 2001

To the Directors of AusBiotech Ltd

I declare that, to the best of my knowledge and belief, in relation to the audit of AusBiotech Ltd for
the year ended 30 June 2012 there have been:

a) no contraventions of the auditor independence requirements of the Corporations Act 2001
   in relation to the audit; and

b) no contraventions of any applicable code of professional conduct in relation to the audit.

[Signature]

Kevin Frederick Proctor – Registered Company Auditor
Proctor Major & Co Pty Ltd
164 Waverley Road, Malvern East VIC 3145

Dated this ___ day of October 2012
AusBiotech Ltd
ABN 87 006 509 726
Independent Audit Report
to the Members of
AusBiotech Ltd

We have audited the accompanying financial report, being a general purpose financial report of AusBiotech Ltd (the company), which comprises the Statement of Financial Position as at 30th June, 2012 and the Statement of Comprehensive Income, Statement of changes in Equity, and Statement of Cash Flows for the year ended on that date, a Summary of Significant Accounting Policies and other explanatory notes and the Directors’ Declaration.

Directors’ Responsibility for the Financial Report
The Directors of the company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards, and the Corporations Act 2001 and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility
Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. These Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company’s preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence
In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001.

Opinion
In our opinion the financial report of AusBiotech Limited is in accordance with the Corporations Act 2001, including:

Giving a true and fair view of the company’s financial position as at 30th June, 2012 and of its performance for the year ended on that date; and

Complying with the Australian Accounting Standards and the Corporations Regulations 2001.


Kevin Frederick Proctor
Registered Company Auditor
Proctor Major & Co Pty Ltd
104 Waverley Rd, East Malvern, VIC, 3145
Dated this 31st day of October 2012
AusBiotech Staff, Committee and Advisory Group Chairs

As at 30 June 2012

Chief Executive Officer
Dr Anna Lavelle Tel: (03) 9828 1400; Email: alavelle@ausbiotech.org

Chief Operating Officer
Mr Glenn Cross Tel: (03) 9828 1402; Email: gcross@ausbiotech.org

Executive Assistant
Ms Jo Beamsley Tel: (03) 9828 1404; Email: jbeamsley@ausbiotech.org

Media and Communications Manager
Ms Lorraine Chiroiu Tel: (03) 9828 1414; Email: lchiroiu@ausbiotech.org

National Manager Programs
Ms Julie Chmielowski Tel: (03) 9828 1425; Email: juliec@ausbiotech.org

Investment Program Manager
Ms Hayley Laing Tel: (03) 9828 1435; Email: hlaing@ausbiotech.org

State-Events Manager
Ms Kirsty Grimwade Tel: (03) 9828 1406; Email: kgrimwade@ausbiotech.org

International Programs & Major Events Manager
Ms Shevaun Duncan Tel: (03) 9828 1409; Email: sduncan@ausbiotech.org

Finance Assistant
Ms Harpreet Kaur Tel: (03) 9828 1408; Email: hkaur@ausbiotech.org

Member Services Manager
Ms Tanya Daw Tel: (03) 9828 1431; Email: tdaw@ausbiotech.org

Company Secretary
Mr Richard Alderson Tel: (03) 9828 1400; Email: raiderson@ausbiotech.org

Web and Data Administrator
Ms Harshini Bellana Tel: (03) 9828 1432; Email: hbellana@ausbiotech.org

AP/NSW Representative
Mr Stephen Pattillo Tel: 0412 709 800; Email: stephenpattillo@bigpond.com

IDO (QLD)
Ms Michelle Nicolson Tel: 0422 844 226; Email: mnicolson@ausbiotech.org

IDO (WA)
Mr Brett Whitecross Tel: (07) 3838 2817; Email: bwhitecross@ausbiotech.org

BRANCH Chairs

NSW Branch
Dr David Irving (Australian Red Cross)
Tel: (02) 9333 3262
Email: dirving@arcbs.redcross.org.au

QLD Branch
Dr Stuart Hazell (Fusidium Pty Ltd)
Tel: 0413 051 601
Email: shazell@fusidium.com

SA Branch
Dr Andrew Milligan (BioSA)
Tel: (08) 8217 6480
Email: andrew.milligan@bioinnovationsa.com.au

VIC Branch
Dr Esra Ogru (Phosphagenics)
Tel: (03) 9565 1142
Email: eogrui@phosphagenics.com

TAS Branch
Dr Anthony Koutoulis (University of Tas)
Tel: (03) 6226 2737
Email: anthony.koutoulis@utas.edu.au

WA Branch
Mr Brian Leedman (pSivida Corp)
Tel: (08) 9443 4849
Email: bleedman@psivida.com

ADVISORY GROUPS

Chair, AusMedtech National Committee
Mr Warren Bingham (Given Imaging)
Email: warren.bingham@givenimaging.com

Chair, Ag, Environmental, Industrial
Mr David (Rock) Hudson (SGA Solutions)
Email: rock@sgasolutions.com.au

Chair, NSW AusMedtech
Ms Lis Boyce (Dibbs Barker)
Email: lis.boyce@dibbsbarker.com

Chair, VIC AusMedtech
Ms Alyssa Grabb (Phillips Ormond Fitzpatrick)
Email: alyssa.grabb@pof.com.au